Doctor users provide about 60% of Docterz’s Rs 5 crore funding

Docterz’s founder built clinic software as a paediatrician. Now a group of doctors who use it has helped finance the company behind it. Around 20 doctor users contributed nearly Rs 3 crore to a Rs 5 crore raise involving approximately 35 investors, according to the original Docterz report from Entrackr on October 29 and the investor and product account from Indian Startup News.

The reports name founder Atish Laddad and describe a platform developed over more than a decade. Its functions include electronic medical records, appointments, billing, vaccination management and patient engagement. The company reports more than 5,000 doctor users in India, with a strong presence in paediatrics. Those usage figures are attributed to the company rather than independently audited by Foundra.

The investor group also includes Vineeta Singh, co-founder and CEO of SUGAR Cosmetics, and Avnish Anand, co-founder and former CEO of CaratLane. They are named participants, not a basis for assigning an undisclosed valuation. The round’s distinctive feature is how much of the financing came from people already using the product in their practices.

Two ways to read the doctor participation

Nearly Rs 3 crore out of Rs 5 crore is approximately 60% of the capital. Around 20 people out of approximately 35 investors is about 57% of the investor count. Both calculations use rounded reported figures, but they describe different things: money and participation. Neither tells us how the individual cheques were distributed.

An average contribution near Rs 15 lakh across the doctor group follows from the same figures. It does not mean every doctor invested Rs 15 lakh. The reports do not disclose enough detail to say who invested most or which participants receive which governance rights. The useful financing observation does not need those missing details invented around it.

Commercially, participation by customers can indicate a willingness to take financial exposure to a supplier they know. It is not a representative survey of all customers. Entrackr attributes one doctor-investor’s decision to his years of using the platform and confidence in the founder. That is a reported individual explanation, not an independent evaluation of every feature or a conclusion about all users.

The overlap of customer and investor also changes how endorsements should be read. Product experience and a financial interest can coexist. A statement of satisfaction may be sincere while still coming from someone who benefits if the business succeeds. Reporting the relationship is more informative than presenting the endorsement as a detached performance audit.

The next product work sits inside an existing workflow

Docterz plans organic expansion, possible acquisitions and AI tools for doctors. The reported development areas include documentation, administrative workflows, practice-data analysis and patient follow-ups. These connect to the existing records and practice-management functions; the accounts do not establish the launch of a diagnostic system. Possible acquisitions also remain possible, rather than an agreement to buy a named company.

The practical product question is how new work would fit a clinic’s existing record. In a hypothetical appointment, information collected before the visit, the practitioner’s notes and later follow-up might need to remain associated with the same patient encounter. A useful automation would have to preserve that relationship rather than merely generate polished text. This is an illustrative requirement, not a reported Docterz demonstration or failure.

That requirement distinguishes product familiarity from evidence for a new release. Current users can know the existing platform well without having tested tools still being developed. The reviewed funding accounts do not provide a benchmark or controlled evaluation for the planned AI functions, so the round should not be treated as their safety test.

The company has attracted money from customers as well as other investors. The funding record makes that relationship visible, while the reported use of proceeds places new product work ahead of it. The doctor-investors have taken a stake in the supplier. The tools to be built with that capital will still need to earn their place in the practice.